In vitro biomimetic HPLC and in vivo characterisation of GM6, an endogenous regulator peptide drug candidate for amyotrophic lateral sclerosis

Klára Valkó, Mark S. Kindy, James A. Evans, Dorothy KoADMET 2018 · DOI

Abstract

Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. Subunits of the 33-amino acid containing motorneurontrophic factor (MNTF) have been investigated and GM6 has been found as a potential peptide therapeutic for ALS. This linear peptide drug candidate has been characterized by HPLC based physicochemical and biomimetic measurements to estimate its in vivo distribution behavior and to estimate its cell penetration and brain to plasma concentration ratio. The free tissue concentration vs time profile has been estimated using the measured physicochemical and biomimetic properties of the intact GM6 molecules and its microsomal stability. The in vitro and in vivo measurements supported the estimated in vivo distribution behavior of GM6.

Introduction

Amyotrophic Lateral Sclerosis (ALS) remains a devastating neurodegenerative condition with limited therapeutic options. While peptide-based drugs offer high selectivity and efficacy, their development is often hindered by poor cell permeability and rapid enzymatic degradation. GM6, a 6-amino acid fragment of the endogenous Motorneurontrophic Factor (MNTF), has emerged as a promising candidate. This study aims to characterize the pharmacokinetic and distribution profile of GM6 to determine its potential for crossing the blood-brain barrier and reaching therapeutic targets in the central nervous system.

Methodology

A biomimetic HPLC approach was utilized to predict the in vivo behavior of GM6. Specialized columns coated with human serum albumin (HSA), alpha-1-acid-glycoprotein (AGP), and phospholipids (Immobilized Artificial Membranes or IAM) were used to simulate drug binding to blood proteins and cell membranes.

Table of equations for calculating ADMET parameters from biomimetic HPLC data.

The retention times from these columns were used in established equations to calculate various ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) parameters. Additionally, the study incorporated:

  • Stability Assays: Measuring metabolic half-life in human plasma and liver microsomes.
  • Quantitative Immunofluorescence: Visualizing cellular entry and localization in iPS-derived human neurons and hepatocytes.
  • In Vivo Studies: Measuring brain penetration in C57BL6 mice using ELISA after a four-hour post-injection period.
  • PK Modeling: Translating mouse data into human dosing estimates using a one-compartment model.

Results and Discussion

The characterization of GM6 revealed several advantageous properties for a neuroprotective agent. Despite being a peptide, GM6 exhibits a positive charge due to its arginine residues, which facilitates strong binding to AGP and phospholipids. This binding profile supports effective tissue partitioning and cellular entry.

Physicochemical and distribution properties of GM6.

Key quantitative findings include:

  • Brain Penetration: An in vivo brain-to-plasma ratio of 1.65, confirming successful crossing of the blood-brain barrier.
  • Volume of Distribution ($V_d$): A value of 7.83 L/kg, indicating extensive distribution into body tissues.
  • Drug Efficiency (DEmax): Calculated at 8.74%, suggesting a high proportion of the dose remains available in its free, active form.
  • Cellular Localization: Immunofluorescence confirmed that GM6 localizes in neurites, the critical projections of motor neurons targeted in ALS.

While GM6 has a relatively short half-life in human blood (~15 minutes), its stability in liver microsomes (70% remaining after one hour) suggests that once it partitions into tissues or the brain, it may persist long enough to exert its therapeutic effects. The study suggests GM6 enters cells via passive partitioning, achieving intracellular concentrations five times higher than extracellular levels.

Conclusion

The multi-faceted characterization of GM6 demonstrates its potential as a viable therapeutic for ALS. Its ability to cross the blood-brain barrier and its high volume of distribution overcome common hurdles in peptide drug development. Future research should focus on renal clearance mechanisms and clinical validation of the estimated human pharmacokinetic profile. Based on mouse efficacy data, a human equivalent dose is estimated at approximately 1.6 mg/kg.

Summary updated

Abstract

Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. Subunits of the 33-amino acid containing motorneurontrophic factor (MNTF) have been investigated and GM6 has been found as a potential peptide therapeutic for ALS. This linear peptide drug candidate has been characterized by HPLC based physicochemical and biomimetic measurements to estimate its in vivo distribution behavior and to estimate its cell penetration and brain to plasma concentration ratio. The free tissue concentration vs time profile has been estimated using the measured physicochemical and biomimetic properties of the intact GM6 molecules and its microsomal stability. The in vitro and in vivo measurements supported the estimated in vivo distribution behavior of GM6.
BibTeX
@inproceedings{valko2018vitro,
  author = {Klára Valkó and Mark S. Kindy and James A. Evans and Dorothy Ko},
  title = {{In vitro biomimetic HPLC and in vivo characterisation of GM6, an endogenous regulator peptide drug candidate for amyotrophic lateral sclerosis}},
  booktitle = {ADMET},
  year = {2018},
  doi = {10.5599/admet.547},
}
Figure